Navigation Links
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Date:11/21/2011

CAMBRIDGE, England, November 21, 2011 /PRNewswire/ --

Phase I Single Dose Study Data Demonstrate Ideal Pharmacokinetic Profile and Excellent Safety and Tolerability

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

The trial is a randomised, placebo controlled Phase I study to investigate the pharmacokinetics, safety and tolerability of orally administered multiple dose regimens of CNV2197944 in both young and elderly volunteers. CNV2197944 is proposed for development initially as a treatment for neuropathic pain and pain associated with osteoarthritis. The study is expected to conclude in 2Q 2012.

The first human single ascending dose Phase I study with orally administered CNV2197944 was recently completed. CNV2197944 was shown to be well absorbed, with an ideal pharmacokinetic profile for the target indication of chronic pain. The compound was well tolerated, with an excellent safety profile.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, commented: "We are really excited to be advancing on schedule to a multiple ascending dose study with this novel, first-in-class treatment for chronic pain.  The data we have seen so far gives us great confidence that CNV2197944 will be a safe and effective long term treatment for chronic pain."

CNV2197944 - a first in class molecule with potential to be a first in class treatment

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Preclinical studies demonstrated that CNV2197944 could have analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
2. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
5. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
6. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
9. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... 21, 2011 Cephalon, Inc. (NASDAQ: CEPH ... Consent Revocation Statement with the Securities and Exchange Commission ... proposals to remove Cephalon,s entire Board of Directors and ... mailed copies of the Statement to shareholders of record ...
... Collins Stewart LLC is pleased to announce the ... Beal Advisors and Liberty Tree Advisors. The purpose of ... and private equity transactions in the healthcare sector. Both ... healthcare advisory firms. Georgia Erbez – founder of Beal ...
... Calif., April 21, 2011 The Stanford University ... the initiation of a Phase 1/2a clinical trial ... allogeneic cell therapy product, SB623, on patients suffering ... For details regarding this clinical trial, please refer ...
Cached Biology Technology:Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 2Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 3Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 4Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 5Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 6Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 7Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 8Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 9Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 10Collins Stewart Announces Formation of Healthcare Investment Banking Alliance 2Collins Stewart Announces Formation of Healthcare Investment Banking Alliance 3Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability 2
(Date:4/23/2014)... to their resumes in an effort to aid the ... issues as genomic science transitions to bedside healthcare, a ... , Until now the plays of Karen H. Rothenberg ... by, their peers and others in the genomics community ... Oxford University Press, publication of the book The ...
(Date:4/23/2014)... Indiana University School of Public Health-Bloomington has bolstered the ... finding a strong association between heme iron, found only ... The study found that heme iron consumption increased the ... no association was found between nonheme iron, which is ... disease. , The study was published online ahead of ...
(Date:4/23/2014)... that male black widow spiders prefer their female mates ... mate preference by male spiders. , The ... Andrade, a professor in UTSC,s Department of Biological Sciences, ... that males overwhelmingly chose to mate with well-fed, unmated ... whether a potential mate is well-fed and unmated by ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Study: Iron consumption can increase risk for heart disease 2Picky male black widow spiders prefer well-fed virgins 2
... benefit from treatment with mixtures of customized antibodies. In ... National Academy of Sciences (USA), a team of Weizmann ... form a web that destroys the cancer cell's communication ... intensive cancer research led to the identification of a ...
... seem to occur on Earth roughly every 26 million ... be caused by rare collisions with comets or asteroids. ... that extraordinary predators are at fault instead. , Adam ... many species competing for both food and living space. ...
... to accurately measure the levels of important chemicals in ... level of a single cell. Scientists at the Carnegie ... the first to overcome this obstacle by successfully applying ... brain chemical levels. The sensors alter their 3-dimensional form ...
Cached Biology News:Two are better than one 2Revolutionary nanotechnology illuminates brain cells at work 2Revolutionary nanotechnology illuminates brain cells at work 3